UTHR - United Therapeutics Corporation

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $636.83 DETAILS

Stock News

United Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

May 19, 2026 11:10 AM • seekingalpha.com

United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of Medicine has published the full results of its TETON-1 study, as well as combined analyses of its TETON-1 and TETON-2 studies, evaluating the use of nebulized Tyvaso for the treatment of IPF. The publication is available here. A summary of the publication was also presented today during a symposium at th.

May 18, 2026 12:15 PM • businesswire.com

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCOMES study are being present

May 17, 2026 11:00 AM • gurufocus.com

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCOMES study are being presented today during the Breaking News: 2026 Clinical Trial Results in Pulmonary Medicine session at the annual meeting of the American Thoracic Society (ATS) International Conference in Orlando. Ralinepag has not been approved for use in any indication by the U.S. Food and Dr.

May 17, 2026 10:15 AM • businesswire.com

United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company's Investigational New Drug application to proceed with a clinical study of its investigational UHeart™ derived from a pig with 10 gene edits. The study, known as EXPRESS, will enroll an initial cohort of up to two participants. United Therapeutics.

May 15, 2026 02:00 PM • businesswire.com

CPRX or UTHR: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks presents investors with the better value opportunity right now?

May 14, 2026 08:41 AM • zacks.com

Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease

/PRNewswire/ -- Varda Space Industries today announced a collaboration with United Therapeutics Corporation (Nasdaq: UTHR) to explore the use of microgravity

May 13, 2026 02:00 AM • prnewswire.com

United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on Tuesday, May 19, 2026, from 9:30 to 9:55 a.m. EST, at the RBC Capital Markets Global Healthcare Conference in New York. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An.

May 12, 2026 03:00 AM • businesswire.com

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference, May 15-20, in Orlando. “We are thrilled to share additional positive data from the TETON-1 study in IPF and the ADVANCE OUTCOMES study in PAH, our pivotal studies that achieve.

May 11, 2026 02:30 AM • businesswire.com

UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook

United Therapeutics shares rise after Q1 earnings miss estimates as investors focus on Tyvaso IPF data and ralinepag's blockbuster potential.

May 07, 2026 09:00 AM • zacks.com

Here Are Thursday’s Top Wall Street Analyst Research Calls: Alcoa, Chiron Real Estate, Clear Secure, Fortinet, Fresh Pet, Kennametal, Oracle, PayPal, United Therapeutics, and More

Pre-Market Stock Futures: Futures are trading modestly higher after a blowout midweek rally spurred by reports that a peace agreement with Iran could be forthcoming soon and by incredible technology earnings and forecasts that destroyed Wall Street estimates. All of the major indices were once again printing new highs as investors cheered the potential for... Here Are Thursday's Top Wall Street Analyst Research Calls: Alcoa, Chiron Real Estate, Clear Secure, Fortinet, Fresh Pet, Kennametal, Oracle, PayPal, United Therapeutics, and More

May 07, 2026 04:14 AM • 247wallst.com

United Therapeutics Corporation (UTHR) Q1 2026 Earnings Call Transcript

May 06, 2026 10:11 AM • seekingalpha.com

United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $5.82 per share, missing the Zacks Consensus Estimate of $6.73 per share. This compares to earnings of $6.63 per share a year ago.

May 06, 2026 04:45 AM • zacks.com

MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPI United Therapeutics plans to be the primary manufacturer of ralinepag DPI MannKind eligible to receive up to $35 million in development milestones plus 10% royalties on net sales DANBURY, Conn.

May 06, 2026 02:30 AM • globenewswire.com

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2026. Total revenues in the first quarter of 2026 decreased by two percent year-over-year to $781.5 million, compared to $794.4 million in the first quarter of 2025. “In the first quarter of 2026, we extended our run of clinical success, with positive results from both our ADVANCE O.

May 06, 2026 02:30 AM • businesswire.com

Ahead of United Therapeutics (UTHR) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Evaluate the expected performance of United Therapeutics (UTHR) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

May 05, 2026 06:15 AM • zacks.com

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

May 04, 2026 09:10 AM • zacks.com

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund launched on June 19, 2006.

Apr 30, 2026 03:21 AM • zacks.com

United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the term for Professor Raymond Dwek, C.B.E., F.R.S., as a member of the Board of Directors will expire at the 2026 Annual Meeting of Shareholders, scheduled for June 26, 2026. Prof. Dwek, who is widely recognized for his pioneering work at Oxford University in the field of glycobiology, joined the United Therapeutics Board in 2002.

Apr 29, 2026 03:00 AM • businesswire.com

United Therapeutics Corporation $UTHR Shares Bought by Comerica Bank

Comerica Bank boosted its position in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 2.4% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 161,683 shares of the biotechnology company's stock after buying an additional 3,731 shares during the period.

Apr 27, 2026 02:00 AM • defenseworld.net